These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 25929843

  • 21. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
    Saffari A, Brösse I, Wiemer-Kruel A, Wilken B, Kreuzaler P, Hahn A, Bernhard MK, van Tilburg CM, Hoffmann GF, Gorenflo M, Hethey S, Kaiser O, Kölker S, Wagner R, Witt O, Merkenschlager A, Möckel A, Roser T, Schlump JU, Serfling A, Spiegler J, Milde T, Ziegler A, Syrbe S.
    Orphanet J Rare Dis; 2019 May 03; 14(1):96. PubMed ID: 31053163
    [Abstract] [Full Text] [Related]

  • 22. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.
    Expert Opin Pharmacother; 2011 Oct 03; 12(14):2265-9. PubMed ID: 21806479
    [Abstract] [Full Text] [Related]

  • 23. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ.
    J Neuropathol Exp Neurol; 2004 Dec 03; 63(12):1236-42. PubMed ID: 15624760
    [Abstract] [Full Text] [Related]

  • 24. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex.
    Cappellano AM, Senerchia AA, Adolfo F, Paiva PM, Pinho R, Covic A, Cavalheiro S, Saba N.
    Childs Nerv Syst; 2013 Dec 03; 29(12):2301-5. PubMed ID: 23743818
    [Abstract] [Full Text] [Related]

  • 25. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S.
    Lancet Oncol; 2014 Dec 03; 15(13):1513-1520. PubMed ID: 25456370
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
    Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, Korf BR, Flamini JR, Kohrman MH, Sparagana SP, Wu JY, Brechenmacher T, Stein K, Berkowitz N, Bissler JJ, Franz DN.
    Nephrol Dial Transplant; 2014 Jun 03; 29(6):1203-10. PubMed ID: 24729041
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
    Ichikawa T, Niida Y.
    No Shinkei Geka; 2022 Jan 03; 50(1):111-121. PubMed ID: 35169091
    [Abstract] [Full Text] [Related]

  • 31. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
    Cheng S, Hawkins C, Taylor MD, Bartels U.
    Pediatr Neurol; 2015 Sep 03; 53(3):238-242.e1. PubMed ID: 26173783
    [Abstract] [Full Text] [Related]

  • 32. Possible prevention of tuberous sclerosis complex lesions.
    Kotulska K, Borkowska J, Jozwiak S.
    Pediatrics; 2013 Jul 03; 132(1):e239-42. PubMed ID: 23733802
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.
    Lancet; 2013 Jan 12; 381(9861):125-32. PubMed ID: 23158522
    [Abstract] [Full Text] [Related]

  • 37. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.
    Yalon M, Ben-Sira L, Constantini S, Toren A.
    Childs Nerv Syst; 2011 Jan 12; 27(1):179-81. PubMed ID: 20703486
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.
    Tyburczy ME, Kotulska K, Pokarowski P, Mieczkowski J, Kucharska J, Grajkowska W, Roszkowski M, Jozwiak S, Kaminska B.
    Am J Pathol; 2010 Apr 12; 176(4):1878-90. PubMed ID: 20133820
    [Abstract] [Full Text] [Related]

  • 40. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Józwiak S, Stein K, Kotulska K.
    Future Oncol; 2012 Dec 12; 8(12):1515-23. PubMed ID: 23231513
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.